头孢哌酮舒巴坦联合莫西沙星治疗老年肺部感染的临床效果研究

Clinical Efficacy of Cefoperazone Sulbactam Combined with Moxifloxacin in the Treatment of Elderly Patients with Pulmonary Infection

目的:研究头孢哌酮舒巴坦联合莫西沙星治疗老年肺部感染的临床效果。方法:以2014年1月至2016年12月于我院就诊的200例老年肺部感染患者为研究对象,将其随机分为观察组与对照组,每组各100例。两组患者均采用叩背吸痰、化痰、吸氧、营养支持等常规治疗方案。对照组静脉滴注头孢哌酮/舒巴坦钠进行治疗,每次3.0 g,每12 h给药1次;观察组联合静脉滴注莫西沙星治疗,每次0.4 g,每天给药1次。两组患者疗程均为2周。观察和比较两组患者的临床疗效、退热时间、止咳时间、肺部啰音消散时间和肺CT病灶吸收时间,治疗前后的血清超敏C反应蛋白水平以及白细胞计数的变化。结果:观察组的治疗总有效率为97.00%(97/100),明显高于对照组[83.00%(83/100)](P<0.05);观察组的退热时间、止咳时间、肺部啰音消散时间以及肺CT病灶吸收时间均明显低于对照组(P<0.05);两组治疗后的血清超敏C反应蛋白水平以及白细胞计数均较治疗前明显降低,且观察组以上指标显著低于对照组(P<0.05);两组患者的不良反应发生率比较无明显差异(P>0.05)。结论:头孢哌酮舒巴坦联合莫西沙星治疗老年肺部感染的临床效果明显优于单纯给予头孢哌酮舒巴坦治疗,不仅可以有效改善患者的临床症状、控制炎症,且具有较高的安全性。

Objective： To investigate the clinical efficacy of cefoperazone sulbactam combined with moxifloxacin in the treatment of elderly patients with pulmonary infection. Methods： 200 cases of patients with pulmonary infection who were treated in our hospital from January 2014 to December 2016 were selected and randomly divided into two groups. Both groups were treated by knocking back sputum, resolving phlegm, oxygen inhalation, nutritional support and aerosol inhalation. The control group received intravenous Cefoperazone sulbactam sodium, the observation group combined with intravenous infusion of moxifloxacin treatment. The clinical treatment effects disappearance time of fever, cough, pulmonary rales, lung CT lesions absorption time, changes of serum high sensitivity C reactive protein and white blood cell count before and after treatment were compared between the two groups. Results： After treatment, the effective rate of observation group was 97.00%（97/100）, which was significantly higher than that of the control group [83.00%（83/100）]（P〈0.05）; the disappearance time of fever, cough, lung rales, the absorption time of lung CT lesion of observation group were significantly lower than those in the control group（P〈0.05）; the serum hypersensitivity C reactive protein levels and WBC count of both groups after treatment were significantly lower than those before treatment（P〈0.05）, which were overtly lower in the observation group（P〈0.05）.There was no significant difference in the incidence of adverse reactions between the two groups（P〉0.05）. Conclusion： Cefoperazone sulbactam combined with moxifloxacin has better curative effect in the treatment of elderly patients with pulmonary infection than cefoperazone sulbactam alone, it can improve the clinical symptoms, control the inflammation with high security.